Eton Pharmaceuticals, Inc. (ETON) Launches Game-Changer for Adrenal Insufficiency
Eton Pharmaceuticals, Inc.
Eton Pharmaceuticals Inc. (ETON)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Opaleye Management James A. Silverman | 2,852,070 | $37,019,869 | 8.24% | |
| 2. | EcoR1 Capital Oleg Nodelman | 1,939,288 | $25,171,958 | +6% | 1.49% |
| 3. | Nantahala Capital Management Wilmot B. Harkey And Daniel Mack | 1,175,951 | $15,263,844 | +6% | 0.61% |
| 4. | Cannell Capital J. Carlo Cannell | 691,367 | $8,973,944 | +82% | 2.99% |
| 5. | Millennium Management Israel Englander | 355,929 | $4,619,958 | +157% | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $15.82 | 2,930 | Large Shareholder | 85,000 | 2025-06-10 | Filing | |
| $15.82 | 5,000 | Large Shareholder | 2,770,000 | 2025-06-10 | Filing | |
| $7.98 | 10,000 | Large Shareholder | 2,770,000 | 2024-10-23 | Filing | |
| $7.03 | 3,970 | Large Shareholder | 82,070 | 2024-10-08 | Filing | |
| $7.03 | 30,000 | Large Shareholder | 2,760,000 | 2024-10-08 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $14.73 | 10,223 | Officer | 612,646 | 2025-06-16 | Filing | |
| $14.77 | 6,800 | Officer | 622,869 | 2025-06-13 | Filing | |
| $14.92 | 16,977 | Officer | 629,669 | 2025-06-12 | Filing | |
| $16.81 | 70,000 | Large Shareholder, Officer, Director | 2,873,513 | 2025-06-05 | Filing | |
| $17.00 | 70,000 | Large Shareholder, Officer, Director | 2,943,513 | 2025-06-04 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 1,100,963 | $14,290,500 | 0% | |
| 2. | 493,650 | $6,407,474 | 1.36% | |
| 3. | 448,804 | $5,825,476 | 0% | |
| 4. | 345,360 | $4,482,773 | 0% | |
| 5. | 319,990 | $4,153,480 | 0% |
News See All
Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Q1 2025 Earnings Call Transcript
Operator: Good afternoon and welcome to Eton Pharmaceuticals First Quarter 2025 Financial Results Conference Call. At this time, all participants are in a listen-only mode.
Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Q4 2024 Earnings Call Transcript
Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Q4 2024 Earnings Call Transcript March 18, 2025Eton Pharmaceuticals, Inc. reports earnings inline with expectations.
14 Best 52-Week High Stocks To Buy According to Analysts
After two years of substantial gains to record highs, exhaustion in the US equity markets is slowly kicking in.
Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Q3 2024 Earnings Call Transcript
Operator: Good afternoon, and welcome to the Eton Pharmaceuticals Third Quarter 2024 Financial Results Conference Call. At this time, all participants are in listen-only mode.
Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Q2 2024 Earnings Call Transcript
Operator: Good afternoon, and welcome to the Eaton Pharmaceuticals Second Quarter 2024 Financial Results Conference Call.
Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Q4 2023 Earnings Call Transcript
Operator: Good afternoon, and welcome to Eton Pharmaceuticals' Fourth Quarter 2023 Financial Results Conference Call. At this time, all participants are in a listen-only mode.
5 High Growth Penny Stocks That Are Profitable
In this article, we will take a look at the 5 high growth penny stocks that are profitable.
Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Q3 2023 Earnings Call Transcript
Operator: Good afternoon, and welcome to the Eton Pharmaceuticals Third Quarter 2023 Financial Results Conference Call.
Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Q2 2023 Earnings Call Transcript
Operator: Good afternoon, and welcome to Eton Pharmaceuticals Second Quarter 2023 Financial Results Conference Call.
Billionaire Hedge Funds
